Eli Lilly’s Vogue World Sponsorship Sparks Backlash Over Weight-Loss Drug Marketing
Eli Lilly’s sponsorship of Vogue World: Milano has triggered sharp criticism from health experts and charities, who argue the partnership normalizes medical weight loss as a beauty standard. While the event featured plus-size models, critics contend the association between a major pharmaceutical brand and high fashion reinforces harmful thinness ideals.
Key points
- Eli Lilly, maker of Mounjaro and Foundayo, was listed as a 'fashion adjacent' sponsor for the fifth Vogue World event in Milan, overseen by Anna Wintour.
- The partnership, which also included the 2025 Hollywood event and the Met Gala livestream, drew fierce backlash from eating disorder charities and academics.
- Critics argue the collaboration normalizes prescription weight-loss drugs as aspirational lifestyle choices, potentially exacerbating body image issues.
- A joint video titled 'Portrait of Progress' links Eli Lilly’s 150-year history with fashion manufacturing, framing health as a precondition for creativity.
- Eli Lilly defended the move as part of its 150th anniversary, stating it aims to shift the conversation from aesthetics to health and challenge obesity stigma.
Background
This controversy unfolds against a backdrop of declining size inclusivity in fashion; a 2025 Vogue Business report found 97.1% of womenswear looks were on straight-size models. Meanwhile, GLP-1 drugs like tirzepatide and semaglutide have seen widespread adoption for aesthetic weight loss, raising concerns about their impact on body image. Eli Lilly holds over 60% of the US diabetes and weight-loss drug market and recently saw its pill approved in the UK.
Why it matters
The intersection of pharmaceutical marketing and high fashion raises significant public health concerns. By associing weight-loss medications with elite cultural events, the industry may inadvertently reinforce the idea that thinness is a medical achievement, potentially worsening eating disorders and undermining progress toward body positivity.
What to watch
Expect continued scrutiny from health advocates and possibly regulatory attention as the normalization of GLP-1 drugs in lifestyle contexts grows. Eli Lilly and Condé Nast may face pressure to clarify the scope of their partnership and its messaging regarding body image.
Want the full story? Read the original reporting
Read on theguardian.com